Evaluation of tests for antibodies against bovine herpesvirus 1 performed in national reference laboratories in Europe

Kramps, J. A.; Banks, M.; Beer, Martin; Kerkhofs, Pierre; Perrin, M.; Wellenberg, G.J.; Oirschot, J.T. van

doi:10.1016/j.vetmic.2004.07.003

Cited by 55 publications

(57 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the presence of neutralizing antibodies in serum does not necessarily correlate with reduction of virus shedding or clinical protection in BoHV-1 vaccinated animals, induction of virus neutralizing antibodies is very often used to access immune responses to vaccination (Kramps et al 2004, Patel et al 2005, Silva et al 2007). The neutralizing antibody titers obtained after two doses of the inactivated 265gE -vaccine were higher than those detected after vaccination with one dose of the attenuated vaccine prepared with the same recombinant (Franco et al 2002a).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Silva

Esteves²,

Dezen

et al. 2009

Pesq. Vet. Bras.

View full text Add to dashboard Cite

Pesq. Vet. Bras. 29(7): 545-551, julho 2009 RESUMO.-[Eficácia de uma vacina inativada, gE-deletada, contra o herpesvírus bovino tipo 1 (BoHV-1).] O Herpesvírus bovino tipo 1 (BoHV-1) é reconhecido como um importante agente de perdas econômicas em bovinos. Vacinação tem sido amplamente empregada para minimizar as perdas conseqüentes a infecções com o BoHV-1. Reportamos previamente o desenvolvimento de uma vacina diferencial para BoHV-1, baseada em um recombinante do qual a glicoproteína gE (gE) foi deletada (265gE -). No presente trabalho foi realizada a avaliação da eficácia de tal recombinante como vacina inativada. Cinco bovinos soronegativos para BoHV-1 foram vacinadas por via intramuscular no dia 0 e revacinadas 30 dias Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE -). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 10 7.0 fifty per cent cell culture infectious doses (CCID 50 ) of 265gE -. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE -recombinant was shown to be suitable for use as a vaccine.INDEX TERMS: Bovine herpesvirus type 1, BoHV-1, recombinant vaccine, inactivated vaccine.Pesq. Vet. Bras. 29 (7)

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Silva

Esteves²,

Dezen

et al. 2009

Pesq. Vet. Bras.

View full text Add to dashboard Cite

show abstract

“…Indeed the strength of the tool is fully dependent on the capacity of the diagnostic test at detecting BoHV-1 gE specific antibody. But the sensitivity of the only available gE specific ELISA is around 70% [97,160]. This rather low level of sensitivity is responsible for 30% false negative answers at individual tests but it remains sufficient to guarantee a high sensitivity at the level of infected herds.…”

Section: The Diva Strategy (Aiming At Differentiating Infected From Vmentioning

confidence: 99%

Bovine herpesvirus 1 infection and infectious bovine rhinotracheitis

et al. 2007

View full text Add to dashboard Cite

-Bovine herpesvirus 1 (BoHV-1), classified as an alphaherpesvirus, is a major pathogen of cattle. Primary infection is accompanied by various clinical manifestations such as infectious bovine rhinotracheitis, abortion, infectious pustular vulvovaginitis, and systemic infection in neonates. When animals survive, a life-long latent infection is established in nervous sensory ganglia. Several reactivation stimuli can lead to viral re-excretion, which is responsible for the maintenance of BoHV-1 within a cattle herd. This paper focuses on an updated pathogenesis based on a molecular characterization of BoHV-1 and the description of the virus cycle. Special emphasis is accorded to the impact of the latency and reactivation cycle on the epidemiology and the control of BoHV-1. Several European countries have initiated BoHV-1 eradication schemes because of the significant losses incurred by disease and trading restrictions. The vaccines used against BoHV-1 are described in this context where the differentiation of infected from vaccinated animals is of critical importance to achieve BoHV-1 eradication.

show abstract

“…This test detects serum antibodies both from vaccine and real infection. The sensitivity (Se) of the method is 95.4% and its specificity (Sp) is 99.0% (Kramps et al, 2004). The controls and cutoff values indicated by the manufacturer were used to score each serum sample as negative (< 45% inhibition) or positive (≥ 45% inhibition).…”

Section: Diagnostic Techniquementioning

confidence: 99%

“…Through eradication programmes, some European Union (EU) countries or regions have managed to reach the status of «IBR-free», and others are presently adopting control or eradication programmes. A third group of countries, including Spain, have no official specific IBR programme (Kramps et al, 2004;Borchers, 2006;Müller, 2006). Given that IBR appears in the World Organization for Animal Health list of bovine diseases and that European countries vary greatly in their IBR status, restrictions are now being imposed to the free circulation of animals and their products among the countries of the EU.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of serum antibodies to bovine herpesvirus-1 in cattle in Galicia (NW Spain)

Eiras¹,

Dieguez²,

Sanjuán³

et al. 2009

Span. j. agric. res.

View full text Add to dashboard Cite

Infectious bovine rhinotracheitis (IBR) is a highly infectious disease of cattle caused by bovine herpesvirus 1 (BHV-1) that causes considerable economic losses to the dairy and beef industry. This report describes the results of two surveys in which prevalence of serum antibodies against BHV-1 in Galicia (NW Spain) was determined. The first was performed on the entire cattle population of the region (year 2000) and the second on the herds included in a voluntary livestock health programme, which comprises IBR, conducted by a group of farms designated ADSG (Health Defence Groups) in this same region (year 2004). Anti-BHV-1 antibodies were determined by anti-gB ELISA in serum samples from all animals aged over one year in the area's dairy and beef herds. Mean individual animal and herd prevalence recorded in 2000 were 38.4% (ranging 37.3%-39.5%; 43.2% dairy, 26.8% beef) and 50.4% (ranging 46.4%-54.4%; 58.3% dairy, 48.1% beef), respectively. Mean true prevalence by herd and animal for the ADSG farms were 47.2% (44.9%-49.5%; 51.5% dairy, 45.2% beef, 42.3% mixed) and 35.7% (35.3%-36.1%; 37.8% dairy, 33.1% beef, 25.5% mixed), respectively. However, the use of non-maker vaccines make difficult to develop a control and eradication program based on serological analysis.Additional key words: BHV-1, IBR, seroprevalence. Resumen Prevalencia de anticuerpos séricos frente al herpesvirus bovino tipo 1 en el ganado vacuno de Galicia (NO España)La rinotraqueitis infecciosa bovina (IBR) es una enfermedad infecciosa del ganado producida por el herpesvirus bovino tipo 1 (BHV-1) que causa considerables pérdidas económicas en la industria láctea y cárnica. Este artículo describe los resultados de dos estudios de prevalencia en los que se determina la presencia de anticuerpos frente al BHV-1 en Galicia (NO de España). El primero fue realizado sobre toda la población bovina de la región (año 2000) y el segundo sobre los rebaños pertenecientes a las asociaciones de defensa sanitaria ganaderas (ADSG) en la misma región (año 2004), que realizan un programa de vigilancia que incluye la IBR. La presencia de anticuerpos se determinó con un ELISA anti-gB en las muestras de suero de todos los animales mayores de 1 año de los rebaños estudiados. Las prevalencias medias por animal y por rebaño halladas en 2000 fueron 38,4% (intervalo 37,3%-39,5%; 43,2% en leche y 26,8% en carne) y 50,4% (intervalo 46,4%-54,4%; 58,3% en leche y 48,1% en carne) respectivamente. La prevalencia real media de rebaño y animal para las granjas de las ADSG fue de 47,2% (44,9%-49,5%; 51,5% en leche, 45,2% en carne y 42,3% en mixtas) y 35,7% (35,3%-36,1%; 37,8% en leche, 33,1% en carne y 25,5% en mixtas) respectivamente. Sin embargo, el uso de vacunas no marcadoras dificulta el desarrollo de programas de control y erradicación basados en el análisis serológico.Palabras clave adicionales: BHV-1, IBR, seroprevalencia.

show abstract

Evaluation of tests for antibodies against bovine herpesvirus 1 performed in national reference laboratories in Europe

Cited by 55 publications

References 5 publications

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Bovine herpesvirus 1 infection and infectious bovine rhinotracheitis

Prevalence of serum antibodies to bovine herpesvirus-1 in cattle in Galicia (NW Spain)

Contact Info

Product

Resources

About